Recent advancements in nanotechnology have opened new avenues in the field of biomedical sciences. The team is excited to announce the successful development of these nanocomposites, representing the world’s first successful integration of lactic acid bacteria components with liquid metal interfaces. The unification of these elements presents a novel therapeutic strategy that effectively engages in both visualization and elimination of cancer cells, a feat that could change the landscape of cancer therapy. This study demonstrates that by leveraging biocompatible materials in the right combinations, researchers can create targeted approaches that seek and destroy cancer at its core.

One of the outstanding features of these liquid metal nanocomposites is their mechanism for selective tumor accumulation, which is primarily driven by the EPR effect. This phenomenon allows for nanoparticles of specific sizes to passively permeate into tumor tissues more readily than into healthy tissues. The structure of the blood vessels within tumor environments is such that they have larger pores than those found in normal tissues, allowing these specially designed nanoparticles to accumulate effectively at the tumor site. The team witnessed promising results, as the developed nanocomposites displayed significant tumor-targeting potential in mouse models implanted with colorectal cancer.

The utility of this innovative treatment is compounded by the use of near-infrared laser light, which augments the nanocomposites’ functionality. Upon exposure to this particular wavelength of light, the indocyanine green component emits fluorescence, enabling clear imaging and accurate diagnosis of cancerous tissues. Moreover, the laser induces localized photothermal effects on the liquid metal within the nanoparticles. This results in high levels of localized heat generation that can effectively kill cancer cells, enhancing the overall treatment impact significantly.

During experimental trials, the efficacy of these nanocomposites was impressively high. The team achieved total cancer elimination within just five days by administering near-infrared light treatment for five minutes daily, without evident side effects. This rapid treatment cycle is not only encouraging but also demonstrates the potential for developing a swift response modality for aggressive cancer types. The dual action of immune modulation through lactic acid bacteria components, combined with the thermal effects generated through liquid metal photothermal conversion, creates a powerful platform for enhanced cancer therapy.

In addition to their impressive therapeutic efficacy, these nanocomposites were rigorously evaluated for biocompatibility and safety. Cytotoxicity assays demonstrated that the nanocomposites exhibited negligible toxicity to both mouse colorectal cancer cells and normal human fibroblasts. Additionally, mouse studies involving blood tests and body weight monitoring revealed minimal adverse physiological effects following intravenous administration, reinforcing the idea that these nanocomposites could lead to safer cancer therapies in clinical settings.

The implications of this research extend beyond immediate treatment options. The team is enthusiastic about the potential for this combination technology to pave the way for innovative cancer diagnostics and therapeutic interventions. By addressing both the detection and treatment of cancer in a singular, integrated approach, the research stands to reshape the future of oncological care. As the understanding of tumor microenvironments grows, so too will the prospects for utilizing naturally occurring bacteria in conjunction with advanced nanomaterials.

The methodology for creating these nanocomposites is another notable achievement. The team developed a straightforward fabrication process that combines the liquid metal alloy (Gallium-Indium) with lactic acid bacterial components and the fluorescent dye, resulting in stable, spherical nanoparticles. This fabrication approach facilitates the continuous production of high-quality nanocomposites while maintaining essential attributes such as stability and membrane permeability.

The discovery prompts several exciting questions regarding future research avenues. Investigating the mechanics of the EPR effect in various types of tumors is crucial for optimizing this strategy across a broader spectrum of cancers. Tailoring the properties of the liquid metal alloys and combining them with various immune-modulating agents could lead to further enhancements and refinements in targeting and therapeutic efficiency.

Furthermore, the directed application of these nanocomposites in clinical settings poses numerous opportunities for accelerated approval processes within oncology. Their ability to target tumors while minimizing systemic toxicity could appeal to regulatory bodies seeking viable solutions for improving patient experiences and outcomes. Continued research could focus on integrating these nanoparticles with other treatment modalities, such as chemotherapy, for a multi-faceted approach to tackle complex tumors effectively.

As demonstrated by the work from Professor Miyako’s team, multidisciplinary collaborations between nanotechnology, immunology, and clinical applications are essential for overcoming present-day barriers to cancer treatment. Bridging gaps between these fields could inspire the next generation of innovative cancer therapies that not only treat but also potentially prevent tumor recurrence. The foresight and ingenuity behind the development of these multifunctional nanocomposites underscore the collective drive toward advancing cancer care through groundbreaking scientific research.

The promising nature of this work reflects a deeper understanding of treatment paradigms that might one day lead to personalized medicine applications. As scientists continue to dissect the complex nature of cancer and its interactions with the immune system, the foundation laid by these nanocomposites can serve as a stepping stone toward further advancements in cancer diagnostics and targeted therapies.

In conclusion, the remarkable achievements stemming from this research highlight the potential for next-generation cancer therapies that combine diagnostics and treatment into one seamless solution. The future of oncology may well be defined by such innovations that utilize the natural capabilities of biological entities and fuse them with cutting-edge technology, paving the way for novel approaches to combat cancer effectively.

Subject of Research: Multifunctional Liquid Metal Nanocomposites for Cancer Treatment
Article Title: Bacterial-adjuvant liquid metal nanocomposites for synergistic photothermal immunotherapy
News Publication Date: September 19, 2025
Web References: https://doi.org/10.1007/s42114-025-01434-7
References: Advanced Composites and Hybrid Materials
Image Credits: Eijiro Miyako from JAIST

Keywords

Cancer immunotherapy, Nanotechnology, Liquid metal nanocomposites, Immunotherapy, Photothermal therapy.

Colorectal cancer continues to pose significant challenges to health systems worldwide due to its high incidence and mortality rates. The search for effective, targeted treatment strategies remains an urgent imperative. In this context, the integration of nanotechnology with microbiome elements has opened a promising avenue of investigation. The use of chitosan nanoparticles (CSNP), a biocompatible and biodegradable polysaccharide derived from chitin, serves as a robust and versatile delivery system. When conjugated with the secretome—the collection of bioactive factors secreted—of the probiotic Lactobacillus acidophilus (L.a-sup), the resultant nanoparticle complex (CSNP/L.a-sup) exhibits striking potential in modulating cancer-related cellular pathways.

The researchers employed an ionic gelation method to synthesize the CSNP/L.a-sup complex. This technique allows for precise control over particle size and distribution, yielding particles averaging 478.6 nanometers in diameter with a negative zeta potential of -8.9 millivolts. Such physicochemical properties are crucial as they influence the biodistribution, cellular uptake, and bioactivity of nanoparticles within biological environments. Scanning electron microscopy further confirmed the morphology and surface characteristics of the nanoparticles, emphasizing their suitability for biomedical applications.

Encapsulation efficiency (EE) metrics revealed that approximately 74.6% of the bioactive proteins from the Lactobacillus acidophilus secretome were successfully incorporated into the chitosan matrices. Moreover, the release profile demonstrated that nearly 76% of these proteins were discharged under mildly acidic conditions (pH ~6.8) within 48 hours. This pH-sensitive release is particularly relevant given the tumor microenvironment’s characteristic acidity, enhancing targeted delivery and therapeutic efficacy while minimizing systemic side effects.

Safety assessment through cytotoxicity analysis indicated a high viability of Caco-2 colon cancer cells and human dermal fibroblast (HDF) cells upon exposure to CSNP/L.a-sup, with survival rates of 85.5% and 92.6%, respectively. These findings underscore the biocompatibility of the nanoparticles, essential for any prospective clinical application. The time-dependent uptake of CSNP/L.a-sup by Caco-2 cells, with significant internalization noted as early as one hour and peaking at three hours, further affirms the efficient cellular internalization dynamics that are vital for therapeutic action.

At the molecular level, the CSNP/L.a-sup exerted significant regulatory effects on key genes implicated in CRC pathogenesis. Notably, there was a marked downregulation of β-Catenin, TGF-α, and TGF-β expression levels, with reductions to 42%, 79%, and 16% of baseline expression, respectively. The suppression of β-Catenin is particularly noteworthy, given its pivotal role in the Wnt signaling pathway, which is frequently dysregulated in colorectal cancer, driving uncontrolled cell proliferation and tumor progression.

Conversely, the nanoparticle complex induced a dramatic upregulation of tumor suppressor genes PTEN and caspase-9, with expression surges of approximately 42-fold and 114-fold, respectively. PTEN functions as a major antagonist of oncogenic signaling cascades, including the PI3K/AKT pathway, and its restoration is associated with reduced tumor growth and metastasis. The amplification of caspase-9 expression signifies enhanced apoptotic activity, facilitating programmed cell death within malignant cells and thus curbing tumor viability.

Interestingly, the differential gene expression patterns imply compartment-specific actions of the nanoparticle components. The suppression of TGF-α seems more intimately linked with the chitosan nanoparticle vehicle itself, while the upregulation of PTEN appears predominantly attributable to the Lactobacillus acidophilus secretome. This suggests a synergistic mode of action where the nanocarrier and its bioactive payload harmonize to maximize anti-cancer effects.

The potential of probiotic-derived secretome factors to influence tumor biology is a frontier area of oncological research. The secretome encompasses a milieu of proteins, peptides, metabolites, and extracellular vesicles that can modulate immune responses, inflammation, and cell signaling pathways. By harnessing this biological reservoir within a nanostructured delivery platform, the study achieves a convergence of advances in microbiology, nanomedicine, and cancer therapeutics.

Beyond in vitro assessments, the implications of this study stretch toward translational and clinical realms. The use of biocompatible materials like chitosan ensures minimal toxicity, while the probiotic secretome offers a rich source of multifunctional biomolecules with intrinsic anti-neoplastic properties. This integrative approach mitigates common limitations in chemotherapy, such as off-target toxicity and drug resistance, opening avenues for safer, more targeted interventions.

Moreover, the observed gene expression modulations correspond closely with pathways implicated in treatment resistance and disease recurrence. By simultaneously dampening oncogenic drivers and bolstering tumor suppressor mechanisms, CSNP/L.a-sup nanoparticles embody a multi-pronged therapeutic strategy, potentially overcoming hurdles that have long impeded colorectal cancer management.

The study’s meticulous characterization of nanoparticle parameters and biological effects establishes a foundation for future optimization, including in vivo validation, pharmacokinetics, and scaling for clinical-grade production. The dynamics of protein release at tumor-relevant pH levels highlight the controlled delivery capabilities essential for maximizing efficacy while minimizing systemic exposure.

Furthermore, the integration of probiotic secretome components aligns with emerging paradigms recognizing the gut microbiome’s influential role in cancer pathogenesis and therapy response. This research exemplifies how leveraging microbiota-derived factors can complement conventional anticancer agents, contributing to a holistic understanding of tumor microenvironment interactions.

Amidst global efforts to expand the oncological arsenal, this study’s contribution is timely and impactful. It not only charts a feasible method to enhance drug delivery using natural polymers but also reveals novel mechanistic insights into probiotic secretome-driven modulation of cancer cell signaling. Such dual-faceted innovation is poised to inspire a wave of biomaterial and microbiome-inspired therapeutic development.

While challenges remain before clinical translation, including comprehensive toxicity profiling and efficacy testing in animal models, the promise of chitosan/Lactobacillus acidophilus secretome nanoparticles heralds a new chapter in precision oncology. The interdisciplinary fusion embodied in this work reflects the future trajectory of cancer research, where nanotechnology, molecular biology, and microbiology converge to combat a complex and devastating disease.

In summary, the research outlined in BMC Cancer reveals that the CSNP/L.a-sup nanoparticle not only modulates pivotal signaling pathways of colorectal cancer but does so with favorable safety profiles and targeted delivery capabilities. This synergistic formulation represents a compelling addition to anticancer strategies, potentially transforming therapeutic outcomes for patients battling CRC worldwide. The promising data serve as a clarion call for further exploration into nano-probiotic therapeutics, advocating a paradigm shift toward bioinspired, multifunctional cancer treatments.

Subject of Research: Anti-cancer effects of chitosan nanoparticles combined with Lactobacillus acidophilus secretome on colorectal cancer signaling pathways in Caco-2 cell line.

Article Title: Anti-cancer properties of chitosan / Lactobacillus acidophilus secretome nanoparticle on signaling pathways of colorectal cancer in colon adenocarcinoma (Caco-2) cell line.

Article References:
Saberpour, M., Maqsoodi, R. & Bakhshi, B. Anti-cancer properties of chitosan / Lactobacillus acidophilus secretome nanoparticle on signaling pathways of colorectal cancer in colon adenocarcinoma (Caco-2) cell line. BMC Cancer 25, 983 (2025). https://doi.org/10.1186/s12885-025-14315-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14315-5